Here we report the discovery of a unique fucosyltransferase (FT) in Caenorhabditis elegans. In studying the activities of FTs in extracts of adult C. elegans, we detected activity toward the unusual disaccharide acceptors Gal␤1-4Xyl-R and Gal␤1-6GlcNAc-R to generate products with the general structure Fuc␣1-2Gal␤1-R. We identified a gene encoding a unique ␣1,2FT (designated CE2FT-1), which contains an open reading frame encoding a predicted protein of 355 amino acids with the type 2 topology and domain structure typical of other glycosyltransferases. The predicted cDNA for CE2FT-1 has very low identity (5-10%) at the amino acid level to ␣1,2FT sequences in humans, rabbits, and mice. Recombinant CE2FT-1 expressed in human 293T cells has high ␣1,2FT activity toward the simple acceptor Gal␤-O-phenyl acceptor to generate Fuc␣1-2Gal␤-R, which in this respect resembles mammalian ␣1,2FTs. However, CE2FT-1 is otherwise completely different from known ␣1,2FTs in its acceptor specificity, since it is unable to fucosylate either Gal␤1-4Glc␤-R or free lactose and prefers the unusual acceptors Gal␤1-4Xyl␤-R and Gal␤1-6GlcNAc-R. Promoter analysis of the CE2FT-1 gene using green fluorescent protein reporter constructs demonstrates that CE2FT-1 is expressed in single cells of early stage embryos and exclusively in the 20 intestinal cells of L 1 -L 4 and adult worms. These and other results suggest that multiple fucosyltransferase genes in C. elegans may encode enzymes with unique activities, expression, and developmental roles.
Fucose-containing glycans are important in a number of biological processes, including their roles as a component of the ligands in mediating leukocyte adhesion to selectins. Mammals possess a number of fucose-containing structures, including those with Fuc␣1-3GlcNAc␤-R, Fuc␣1-6GlcNAc␤-R, and Fuc␣1-2Gal␤-R (1, 2). These linkages are generated by a variety of ␣-fucosyltransferases (FTs) 1 derived from a surprisingly high number of genes. Humans have at least six different ␣1,3FT genes (III, IV, V, VI, VII, and IX), two ␣1,2FT genes (FUT1 (H) and FUT2 (Se) and an ␣1,2FT pseudogene (SECI)), and at least one ␣1,6FT gene (3) (4) (5) . The functions of all of these genes and their cognate fucose-containing glycans are not well understood, but the expression of many of these genes is developmentally regulated and is altered during embryonic development, differentiation, and tumorigenesis. Although genetic approaches in mice have revealed many important insights into the functions of many different genes, particularly in regard to the ␣1,3FTs and their role in generating cell adhesion ligands (5, 6) , genetic approaches to study glycoconjugate roles in development have been frustrated by the complexity of the large multigene families for most of the glycosyltransferases and consequent enzyme redundancy. This situation has led to the consideration of model systems that may accelerate our understanding of the overall biological functions of fucose-containing glycoconjugates.
Caenorhabditis elegans is a highly attractive model system in which to study the potential developmental roles of glycoconjugates, since the worm shares many fundamental biological and biochemical pathways with higher organisms. The potential of using C. elegans to investigate the roles of glycoconjugates in development requires the identification and characterization of specific glycosyltransferases and their cognate structures, which may be important in developmental processes. During the past few years, many different enzymes involved in glycoconjugate biosynthesis have been identified by homology in C. elegans (1) . In our previous studies, we identified an ␣1,3FT and an ␣1,2FT activity in C. elegans extracts (7) . However, further analysis of the acceptor specificity demonstrates that C. elegans has a novel ␣-1,2FT activity toward the unusual acceptors Gal␤1-4Xyl␤-R and Gal␤1-6GlcNAc-R to synthesize the Fuc␣1-2Gal␤1-R products; such acceptor specificity would be unique among known ␣1,2FTs. However, recent studies on the O-glycans of C. elegans glycoproteins document the occurrence of such Fuc␣1-2Gal␤1-R linkages (8) . Searches of the C. elegans genome revealed that dozens of putative fucosyltransferase genes are present (3) , and the C. elegans genome contains at least 22 different genes encoding putative ␣1,2FTs with some identity to mammalian ␣1,2FTs.
In this paper, we report our identification of the C. elegans gene (termed CE2FT-1) encoding the ␣1,2FT (CE2FT-1) capable of fucosylating the disaccharide acceptors Gal␤1-4Xyl␤-R and Gal␤1-6GlcNAc-R but unable to fucosylate lactose. Preliminary studies on other members of this putative ␣1,2FT family in C. elegans suggest that they differ from CE2FT-1 in acceptor specificity. The expression pattern of CE2FT-1 is also unusual and is limited strictly to the 20 intestinal cells in the adult worm. These unexpected findings suggest that each of the FTs in C. elegans may have a unique enzyme activity and role in development.
EXPERIMENTAL PROCEDURES
Materials-Sodium cacodylate, MnCl 2 , ATP, L-fucose, phenyl-␤-DGal, GlcNAc␤-pNP, GalNAc␤-O-pNP, and Xyl␤-O-pNP were purchased from Sigma. ␣1,2-Fucosidase and ␣1,3-fucosidase were purchased from Prozyme, Inc. (San Leandro, CA). ␣1,6-Fucosidase and GDP-fucose were purchased from Calbiochem. Gal␤-O-pNP, Gal␣-O-pNP, and Glc␤-Mu (methylumbelliferon) were obtained from NBS Biologicals Ltd. (Huntingdon, UK). Gal␤1-4Glc␤-O-pNP, Gal␤1-4GlcNAc␣-Bz, Gal␤1-4GlcNAc␤1-2Man␣-pNP, Gal␤1-3(Fuc␣1-4)GlcNAc, and Gal␤1-3GlcNAc␣-O-pNP, and Gal␤1-3GalNAc␣-O-pNP were purchased from Toronto Research Chemicals Inc. (Downsview, Canada). Gal␤1-3GlcNAc␤1-3Gal␤1-4Glc was from Oxford GlycoSystems. Gal␤1-4GlcNAc␤1-3Gal␤1-4GlcNAc was from Dr. A. Veyrieres (Universite Paris Sud, Orsay, France). Gal␤1-3Gal␤1-4Glc was from Dr. M. Messer (University of Sydney). Gal␤1-3Gal␤1-4Xyl-O-Bzl and Gal␤1-4Xyl-O-Bzl were from Dr. T. Norberg (Swedish University of Agricultural Sciences, Uppsala, Sweden). LNFII/III (mixture of Gal␤1-3(Fuc␣1-4)GlcNAc␤1-3Gal␤1-4Glc (LNFII) and Gal␤1-4(Fuc␣1-3)GlcNAc␤1-3Gal␤1-4Glc (LNFIII)) and Gal␤1-6GlcNAc were from Dr. D. van Cloning and Expression of CE2FT-1-The oligonucleotides 5Ј-GTA-TGAGAAATGTGAAAGGACTTTTTAGC-3Ј and 5Ј-CATCTATTTTTGA-AATTATCGACC-3Ј were used as forward and reverse primers, respectively, to amplify the CE2FT-1 coding sequence from a C. elegans cDNA library in the ZAP vector (provided by Dr. Robert Barstead, Oklahoma Medical Research Foundation, Oklahoma City, OK). Reaction mixtures for amplification by TaqDNA polymerase contained a 1 M concentration of each primer, 200 M dNTPs, 2.5 mM MgCl 2 , and 1 l of 10 9 plaque-forming units/ml C. elegans adult cDNA library in a final volume of 100 l. Amplification was carried out by an initial denaturing step of 94°C for 5 min, followed by 35 cycles of 94°C for 1 min, 59°C for 1 min, and 72°C for 2 min. These cycles were then followed by an extension period of 72°C for 7 min. Following amplification, the PCR product was run on an agarose gel, and the ϳ1060-bp DNA band was excised from agarose gel and purified by a QIAEX II agarose gel extraction kit. The purified DNA was ligated into the pCR3.1 vector and subsequently transformed into One Shot Top10FЈ competent cells according to the procedures provided with the bidirectional eukaryotic TA cloning kit. Clones containing inserts were selected and amplified, and minipreps were prepared using Qiagen kits (Qiagen, Inc., San Clarita, CA) and digested with ApaI restriction enzyme to check the direction of the inserts. The clones with right direction insert were sequenced by the Oklahoma Medical Research Foundation Facility (Oklahoma City, OK).
The clone with full-length cDNA of CE2FT-1 was then digested with BamHI and XhoI, subcloned in frame into pcDNA4/HisMax C vector, and subsequently transformed into One Shot Top10FЈ competent cells. The clones containing right inserts were selected and amplified, and maxipreps were prepared using the Qiagen endotoxin-free plasmid DNA purification kit.
To determine whether the cloned insert encoded an active ␣1,2FT, human 293T cells were transfected with 4.5 g of plasmid DNA harboring CE2FT-1 cDNA (in the plasmid pcDNA4/HisMax C) using FuGene 6 transfection reagent, as described by the manufacturer (Roche Molecular Biochemicals). Mock-transfection was carried out by transfecting 293T cells with pcDNA4/HisMax C vector. Seventy-two hours after transfection, cells were harvested, solubilized in 50 mM sodium cacodylate buffer containing 1% Triton X-100, and assayed for fucosyltransferase activity as described below.
Construction of an Expression Vector Encoding C-terminal HPC4 Epitope-tagged CE2FT-1-A mammalian expression vector of pcDNA4/HisMax (Invitrogen) encoding C-terminal HPC4 epitopetagged CE2FT-1 was constructed using PCR for introducing the 12-amino acid Ca 2ϩ -dependent HPC4 epitope (9, 10) into the cDNA. The forward primer was T7 (5Ј-TAATACGACTCACTATAGGG-3Ј). The reverse primer-containing sequence, encoding 12 amino acids of the HPC4 epitope (EDQVDPRLIDGK) immediately following the Cterminal lysine of CE2FT-1, was 5Ј-CGGAATTCTACTTGCCGTCGAT-CAGCCTGGGGTCCACCTGG-TCCTCTTTTGAAATTATCGACCCGT-TTCGTGAC-3Ј. The PCR was performed by denaturation at 94°C for 2 min, amplification for 30 cycles at 94°C for 1 min, 56°C for 1 min and 72°C for 2 min using plasmid pcDNA4/HisMaxC/CE2FT-1 cDNA as the template. The expected 1420 bp of PCR product was purified on 1.2% TAE-agarose gel and digested by EcoRI and ApaI. The expected 1000-bp DNA fragment was purified and cloned into ApaI (partially digested)/ EcoRI sites of pcDNA4/HisMaxC/CE2FT-1cDNA plasmid, and its sequence was confirmed. Human 293T cells were transiently transfected with 4.5 g of plasmid DNA harboring CE2FT-1 cDNA with the HPC4 epitope tag fused to the C terminus (in the plasmid pcDNA4/HisMax C) using FuGene 6 transfection reagent. Seventy-two hours after transfection, cells were harvested and solubilized in 50 mM sodium cacodylate buffer containing 1% Triton X-100, and the expressed CE2FT-1 was purified on immobilized HPC4 monoclonal antibody from the cell extracts. Following purification, the epitope-tagged CE2FT-1 was analyzed by Western blotting using the HPC4 antibody and was assayed for fucosyltransferase activity as described below.
Fucosyltransferase Assay-Standard fucosyltransferase assays were performed in a 50-l reaction mixture containing 5 mol of sodium cacodylate (pH 7.2), 1 mol of MnCl 2 , 0.2 mol of ATP, 5 nmol of GDP-[
14 C]Fuc (3.6 Ci/mol), 0.2% (v/v) Triton X-100, and 15 l of cell extract. Acceptor substrate concentrations were as indicated. After incubation for 120 min at 37°C, the reaction was stopped, and the product was separated from unincorporated label by chromatography on a 1-ml column of Dowex 1-X8 (Cl Ϫ form) as described (11, 12) ; alternatively, for substrates with a hydrophobic aglycon, the products were isolated by adsorption to Sep-Pak C-18 cartridges (Waters; Milford, MA), washed with water, and eluted with absolute methanol, as described (13) . Control assays lacking the acceptor substrate were carried out to correct for incorporation into endogenous acceptors, and assays with mock-transfected cells were conducted to correct for endogenous fucosyltransferase activity.
C. elegans Culture and Preparation of Extracts-The standard laboratory wild type strain N 2 worms were grown on NGM plates seeded with OP50 bacteria to obtain lots of mixed stage worms. Worms were washed with M9 buffer and were frozen in liquid nitrogen for 2 min, and the worm pellets were stored at Ϫ80°C. For C. elegans extracts, frozen worms were ground and suspended in 50 mM sodium cacodylate buffer, pH 7.0, containing 1 tablet/10 ml complete protease inhibitor mixture (Roche Molecular Biochemicals), 1% Triton X-100 and then subjected to sonication (three pulses of 10 s each) on a cell disruptor (Branson Sonic Power Co.). The homogenate was incubated on ice for 30 min to allow solubilization of proteins and then centrifuged at 14,000 rpm at 4°C for 10 min. The supernatant fractions were collected, and they were either used directly or stored as aliquots at Ϫ80°C. Frozen extracts were thawed only once for use in enzyme assays.
Characterization of Fucosyltransferase Assay Products-Products obtained with the acceptor Gal-␤-phenyl, GDP-[ 3 H]Fuc, and 293T cell extracts expressing recombinant CE2FT-1 were isolated by chromatography on Sep-Pak C-18 cartridges (Waters). The isolated, radiolabeled products were incubated with 0.8 milliunits of ␣1-2-fucosidase, ␣1-3,4-fucosidase, and ␣1,6-fucosidase in 20 l of reaction buffer 5 (Prozyme, Inc.) at 37°C for 48 h. Following treatment, the samples were analyzed by descending paper chromatography in a solvent system of ethyl acetate/pyridine/acetic acid/water (5:5:1:3). Products obtained upon incubation of C. elegans extracts with the acceptors Gal␤1-3Gal␤1-4Xyl-O-Bzl, Gal␤1-4Xyl-O-Bzl, Gal␤1-3GalNAc␣-O-pNP, and the donor GDP-[ 3 H]Fuc were isolated by chromatography on Sep-Pak C-18 cartridges. The isolated, radiolabeled products were incubated with 0.8 milliunits of ␣1-2-fucosidase, ␣1-3,4-fucosidase, ␣1,6-fucosidase, and water (mock treatment) in 50 l of reaction buffer 5 (Prozyme) at 37°C for 48 h, respectively. After treatment, the samples were isolated by adsorption to Sep-Pak C-18 cartridges (Waters), washed with water, and eluted with absolute methanol, and the radioactivity in the eluted material was determined by scintillation counting. The percentage of [ 3 H]fucose released was calculated based on the mock treatment.
Preparation of DNA Constructs for Promoter Analysis-We prepared fusion constructs of the upstream promoter sequences of CE2FT-1 fused to the green fluorescent protein to examine the spatial pattern of CE2FT-1 expression during C. elegans development. A 700-bp fragment of genomic sequence containing the putative promoter region immediately upstream of the initiation site for CE2FT-1 translation was obtained by PCR using C. elegans genomic DNA as template with the primers 5Ј-AAAAAATTCATTATATAACATTTGTTTTCAG-3Ј, and 5Ј-ACTTAAAAAAAATACCGGAAC-3Ј. The PCR product was run on an agarose gel, and an ϳ700-bp DNA band was excised from agarose gel and purified by the Qiagen agarose gel extraction kit. The purified DNA was ligated into pCR3.1 vector and subsequently transformed into Top10FЈ competent cells. Clones containing inserts were selected and amplified, and minipreps were prepared using the Qiagen kit and then sequenced. The clone containing the right insert was digested with HindIII/XbaI and subcloned into pPD95.67 vector (originally provided by Dr. Andrew Z. Fire (Carnegie Institute of Washington, Baltimore, MD)), creating plasmid pPD95.67/CE2FT-1-prom.
Preparation of Transgenic Worms and Promoter Analysis-DNA injection into the C. elegans germ line was carried out as described (14, 15) . Transgenic lines were established from F2 descendants of animals injected with 10 ng/l CE2FT-1::GFP constructs (pPD95.67/CE2FT-1-prom), and pBX, which carries the PHA-1 gene, which is involved in the development of the pharynx, served as a transformation marker.
Preparing Synchronous Culture of L 1 and L 2 -L 4 Young Adult Worm-N 2 worms were grown on NGM plates seeded with OP50 bacteria to obtain lots of gravid adults. These were incubated with 5 ml of alkaline bleach (0.25 M KOH, 25% commercial Clorox) at room temperature for 3 min with occasional gentle agitation. This procedure kills all adults and larvae but leaves the eggs alive. The eggs were washed with M9 buffer and centrifuged for 1 min in a clinical centrifuge at 1800 rpm. The supernatant was removed, and the washing was repeated two times. The washed eggs were distributed to one unseeded plate, which was incubated at 20°C overnight. This allows the eggs to hatch and arrests the animals as starved L 1 , which produces synchrony of the population. Growth was restarted by distributing these starved L 1 onto plates seeded with an adequate amount of food to allow the animals to grow without starving. At times during growth, worms were harvested to generate populations of L 2 -L 4 and young adult worms.
RT-PCR and Quantitative Real Time RT-PCR Analysis of C. elegans CE2FT-1 mRNA during Development-Total RNA was extracted from staged synchronous populations using a total RNA isolation kit (Ambion, Austin, TX). Random primed first strand cDNA was synthesized from 2 g of total C. elegans RNA using the SuperScript preamplification system for first strand cDNA synthesis kit (Invitrogen). The first strand cDNA was used as a template in PCRs to amplify cDNAs encoding CE2FT-1 transcripts using the oligonucleotides 5Ј-GTATGAGAAA-TGTGAAAGGACTTTTTAGC-3Ј and 5Ј-CATCATTTTTGAAATTATCG-ACC-3Ј in the reactions containing 3 l of first strand cDNA in a volume of 50 l. For controls, a C. elegans actin gene-specific primer pair 5Ј-G-ACAATGGATCCGGAATGTGC-3Ј and 5Ј-ATGATGGAGTTGTAAGAA-GTCTC-3Ј was used to amplify the C. elegans actin gene in the identical conditions described. Following PCR amplification, 20 l of each PCR product was run on a 1.5% agarose gel containing 10 g/ml ethidium bromide. Quantitative RT-PCR was performed using an ABI Prism 7700 sequence detection (PerkinElmer Life Sciences) using the doublestranded DNA binding dye, SYBR Green. Random primed first strand cDNA was synthesized in a 100-l reaction from 2 g of the total C. elegans RNA using TaqMan Reverse Transcription Reagents (PerkinElmer Life Sciences). The first strand cDNA was used as a template in PCRs to amplify cDNAs encoding CE2FT-1 transcripts using gene-specific primers 5Ј-GTATGAGAAATGTGAAAGGACTTTT-TAGC-3Ј and 5Ј-CCCATCCTATTAACAATGAAAATTATGA-3Ј, designed by using Primer Express software, in the reactions containing 5 l of first strand cDNA and 25 l of 2ϫ SYBR Green Master Mix (PerkinElmer Life Sciences) in a volume of 50 l. For controls, a C. elegans actin gene-specific primer pair 5Ј-ATC GTC CTC GAC TCT GGA GAT G-3Ј and 5Ј-TCA CGT CCA GCC AAG TCA AG-3Ј was used to amplify the C. elegans actin gene in the identical conditions described. Cycling parameters were 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. To confirm the absence of nonspecific amplification, The PCR products were analyzed by a 1.2% agarose gel containing 10 g/ml ethidium bromide.
RESULTS

Identification of a Fucosyltransferase Gene in C. elegans-
Our previous studies indicated that extracts of C. elegans contain an unusual ␣1,3FT activity and in addition contained an unidentified ␣1,2FT activity (7). To gain a better understanding of the types of fucosyltransferases present in C. elegans, we used a panel of acceptors to assay extracts of adult worms for possible fucosyltransferase activities with radioactive GDPFuc as the donor (Table I ). The highest activity was found toward the vertebrate type 1 O-glycan structure Gal␤1-3Gal-NAc␣-O-pNP (Table I ). However, high activity was also detected toward the unusual disaccharide Gal␤1-4Xyl␤-O-benzyl. This disaccharide represents part of the core structure of Gal␤1-4Xyl␤-O-R found in vertebrate proteoglycans. We considered that the enzyme capable of fucosylating the acceptors Gal␤1-3GalNAc␣-O-pNP and Gal␤1-4Xyl␤-O-benzyl in C. elegans extracts might be an ␣1,2FT acting on the terminal nonreducing Gal residue rather than the penultimate GalNAc or Xyl residues.
To identify C. elegans sequences with possible homology to known ␣1,2FTs, we compared the amino acid sequences of human, rabbit, pig, and mouse ␣1,2FTs to identify potential conserved sequences among them. We then used these identified conserved domains in a BLAST search of the C. elegans genome data base. One of the genes identified is harbored in C. elegans cosmid EGAP9 (GenBank TM accession number U80026), derived from chromosome V, encoding a predicted cDNA of 1068 bp encoding the hypothetical protein EGAP9.2. A map of the gene structure is shown in Fig. 1A , and the overall gene size is 1814 bp, including 700 bp of the 5Ј upstream sequence. The open reading frame is encoded within 10 exons predicted to encode a protein with 355 amino acids (Fig. 1B) . (16). The exon/intron junctions at all introns follow the GT/AG rule, although it has been predicted that not all splicing for short introns in C. elegans requires the AG (17) . There are three predicted N-glycosylation sites at positions in the predicted luminal domain of the protein at Asn residues 92, 311, and 349 within the N-glycosylation sequon Asn-X-Ser/Thr (where X does not represent Pro). There are no predicted sites for O-glycosylation at Ser and Thr residues, using the NetOGlyc 2.0 Prediction Server (available on the World Wide Web at www.cbs.dtu.dk/services/NetOGlyc/) for O-glycosylation sites, although this program is predictive for mammalian glycoproteins.
The Kyte-Doolittle hydrophilicity plot (18) of the protein sequence suggests the presence of a 16-amino acid transmembrane domain at the N terminus (Fig. 2) . Thus, the encoded protein displays the typical hallmarks of most Golgi-localized glycosyltransferases (i.e. type II membrane orientation with a relatively small cytosolic N terminus and a large, extracellular, C-terminal region) (1). The most conserved region predicted between the CE2FT-1 and other ␣1,2FTs is in the C-terminal domain (Fig. 3) , indicating that this region is likely to contain the catalytic domain, as seen for other Golgi glycosyltransferases. However, overall the predicted amino acid sequence from the CE2FT-1 cDNA displays a relatively low identity (5-10%) to the ␣1,2FT sequences in humans, rabbits, and mice at the amino acid level (Fig. 3) .
Cloning of the cDNA from C. elegans Encoding CE2FT-1-Gene-specific primers were designed to amplify the entire coding sequence of the C. elegans CE2FT-1 from a C. elegans cDNA ZAP library, as described under "Experimental Procedures." Following amplification, the PCR product was TA-cloned into the vector pCR3.1 and then subcloned in frame into pcDNA4/HisMax C mammalian expression vector. A clone was isolated, and DNA sequencing confirmed the exon/intron boundaries predicted by the data base.
Expression of C. elegans CE2FT-1 cDNA in the 293T CellTransfection of human 293T cells with cDNA encoding CE2FT-1 results in significantly higher enzyme activity over mock-transfected 293T cells by using Gal-␤-p-nitrophenol as the acceptor (Table I ). The mock-transfected 293T cells have no significant endogenous ␣1,2FT activity. To verify that the activity is due exclusively to the expressed cDNA and not to alteration of an endogenous, unknown enzyme, we used Western blot with Anti-Xpress monoclonal antibody to probe the Xpress-tagged CE2FT-1 in cell extracts from transfected 293T cells. Unexpectedly, the results indicated that the N-terminal Xpress tag fused to the N terminus of CE2FT-1 was cleaved, since little antigenic protein was detected. We then constructed an alternative full-length cDNA of CE2FT-1 with the Ca 2ϩ -dependent HPC4 epitope (9, 10) tag fused to the C terminus. Human 293T cells were transiently transfected with this construct, and the transfected cells were harvested 72 h after transfection. The presence of the HPC4 epitope-tagged CE2FT-1 protein with a molecular mass of ϳ50 kDa was identified by Western blot using the Ca 2ϩ -dependent HPC4 monoclonal antibody (Fig. 4) . The recombinant HPC4 epitope-tagged CE2FT-1 was purified by absorption on immobilized HPC4 (9, 10). Using GDP[
3 H]Fuc as the donor and Gal␤-phenyl as the acceptor, the immunoabsorbed recombinant HPC4-tagged CE2FT1 generated 2467 cpm of product, whereas immunoabsorption from mock-transfected cells generated a background of 58 cpm. These results confirm that the protein encoded by the gene CE2FT-1 is an active ␣1,2FT. To confirm the fucosyl linkages in the reaction product generated by CE2FT-1, the [ 3 H]Fuc-labeled product was isolated and treated with either ␣1,3/4-fucosidase, ␣1,2-fucosidase, or ␣1,6-fucosidase, followed by descending paper chromatography. Treatment of the product with ␣1,2-fucosidase, but neither the ␣1,3/4-fucosidase nor ␣1,6-fucosidase, caused the quantitative release of [ 3 H]fucose from the radiolabeled product (Fig. 5A) . These results demonstrate that the product of CE2FT-1 contains Fuc in ␣1,2-linkage to the Gal residue and demonstrate that CE2FT-1 encodes a functional ␣1,2FT.
Acceptor Specificity of Recombinant CE2FT-1-To further characterize the CE2FT-1 activity, a comprehensive analysis of the acceptor specificity of CE2FT-1 was performed, using a large variety of acceptors, many of which are known to be acceptors for previously described ␣1,2FTs. CE2FT-1 transfers fucose to the monosaccharide acceptor Gal-␤-p-nitrophenol but not to Gal-␣-p-nitrophenol, indicating absolute specificity for terminal ␤-linked Gal residues (Table I) . However, unexpectedly CE2FT-1 is completely inactive in using Gal␤1-3Gal-NAc␣-O-pNP as the acceptor and is also inactive in using either lactose or Gal␤1-4Glc␤-O-pNP as acceptors. In addition, the enzyme is unable to transfer fucose to terminal ␤1-4-linked galactosyl residues in Man-containing branched complex-type N-glycans. The enzyme was also inactive with the acceptors containing ␣1-3/4-linked fucose, such as LNFII/III and Gal␤1-3(Fuc␣1-4)GlcNAc, indicating that the CE2FT-1 is unable to transfer Fuc in ␣1,2 linkage to another fucose to generate Fuc␣1-2Fuc␣1-R, as seen for at least one other invertebrate ␣1,2FT (19) . By contrast, the enzyme demonstrated a clear preference for the unusual acceptor Gal␤1-4Xyl␤-O-benzyl with about one-third less activity demonstrated toward Gal␤1-6GlcNAc. Importantly, neither of these acceptors has been reported to be an acceptor for previously described ␣1,2FTs. CE2FT-1 showed some activity toward two of the more complex acceptors with the sequences Gal␤1-3Gal␤1-4Xyl␤-O-benzyl and Gal␤1-3Gal␤1-4Glc (Table I ). These two latter acceptors contain a penultimate Gal residue rather than GlcNAc, as in two of the acceptors that were inactive, the trisaccharide Gal␤1-4GlcNAc␤1-2Man␣-pNP and the tetrasaccharide Gal␤1-4GlcNAc␤1-3Gal␤1-4GlcNAc. Overall, CE2FT-1 is inactive toward all acceptors with penultimate GlcNAc or Glc residues (Table I ). Thus, it is possible that the enzyme does not recognize acceptors with penultimate GlcNAc residues but prefers those with terminal Gal and a penultimate residue that is neither GlcNAc nor Glc. However, insufficient amounts of product were generated to allow proof at this time as to which of the Gal residues was modified by Fuc in reactions with CE2FT-1. Nevertheless, these results demonstrate that CE2FT-1 is unique compared with known ␣1,2FTs in its acceptor specificity, since all previously described ␣1,2FTs are efficient in using lactose or virtually any other acceptor with terminal ␤1-4-or ␤1-3-linked galactose residues (20, 21) . The acceptor specificity of CE2FT-1 suggests that the presence of an unsubstituted C-6 hydroxyl group on the penultimate sugar hinders enzyme recognition of the terminal Gal residue.
The activity of CE2FT-1 was compared with other endogenous potential ␣1,2FTs in extracts of adult C. elegans. These extracts contained a fucosyltransferase activity toward the same acceptors identified for CE2FT-1, but in addition, the extracts contained fucosyltransferase activity toward Gal␤1-4GlcNAc␣-benzyl and the O-glycan type acceptor Gal␤1-3Gal-NAc␣1-O-pNP (Table I) . It is likely, based on our previous studies (7) , that Gal␤1-4GlcNAc␣-benzyl is fucosylated by the ␣1,3FT CEFT-1 or related ␣1,3FTs rather than an endogenous ␣1,3FT activity. These results suggest that adult worms express an active form of both CE2FT-1 and potentially other fucosyltransferases active toward Gal␤1-4GlcNAc␣-benzyl and Gal␤1-3GalNAc␣1-O-pNP. Interestingly, the extracts did not contain significant fucosyltransferase activities toward Gal␤1-4Glc␤-O-pNP. This disaccharide is an excellent acceptor for the known ␣1,2FTs found in vertebrates, which suggests that of the many potential ␣1,2FTs encoded by the C. elegans genome (3), none of these enzymes efficiently utilize the common acceptor Gal␤1-4Glc␤-O-pNP. To confirm that the fucosyltransferase reaction products using these acceptors were modified by endogenous ␣-1,2FTs in the C. elegans extracts, we isolated the products generated by the C. elegans extracts using three of the acceptors utilized by the recombinant CE2FT-1. The acceptors we chose were Gal␤1,3GalNAc-pNP, Gal␤1,4Xyl-Bzl, and Gal␤1,3Gal␤1,4Xyl-Bzl. These 3 H-fucosylated products generated by the endogenous ␣-fucosyltransferases in C. elegans extracts were treated with either ␣-1,2-fucosidase, ␣-1,3/4-fucosidase, or ␣-1,6-fucosidase. [ 3 H]Fucose was quantitatively released from all of the products by ␣-1,2-fucosidase, and only minimal radioactivity was released by the other ␣-fucosidases (Fig. 5B) . These results indicate that the predominant endogenous ␣-fucosyltransferase in C. elegans extracts is an ␣-1,2FT with the type of acceptor specificity exhibited by recombinant CE2FT-1.
Expression of CE2FT-1 Promoters at Various Stages in C.
elegans Development-Very little is known about the functions of glycosyltransferases in C. elegans (7, (22) (23) (24) (25) (26) , and no information is available about expression of potential ␣1,2FT genes. To examine whether CE2FT-1 is expressed during development and its pattern of expression, we first analyzed transcript levels by relative RT-PCR using equivalent amounts of total RNA from different developmental stages (Fig. 6A) . The CE2FT-1 gene is expressed at all developmental stages with little relative difference in expression compared with ␣-actin. Since there are more than 22 putative ␣1,2FTs in C. elegans, and some of them with more than 85% homology to CE2FT-1, we performed quantitative RT-PCR to analyze the mRNA expression level at the different stages. The results indicated that there is little relative difference in expression at different stages (see Fig. 6, B and C) .
To localize the expression of the gene, we used reporter promoter constructs driving expression of the coelenterate green fluorescent protein (GFP) in the vector pPD95.67/ CE2FT-1-prom. The promoter construct consisted of a 5Ј 700-bp fragment containing all the upstream genomic sequence, which should encompass the putative promoter region immediately upstream of the initiation site for CE2FT-1 translation (Fig. 1A) . In rats, it has been shown that expression of the ␣1,2FT gene is regulated by functional promoter elements within the 5Ј-flanking region of that gene (27) . Likewise, in C. elegans, gene expression is usually regulated by promoter elements in 5Ј-untranslated regions of genes (14) . Expression of the GFP reporter gene in the transgenic worms injected with CE2FT-1 promoter construct pPD95.67/CE2FT-1-prom was examined (Fig. 7, A-H) . The results indicate that the promoter for CE2FT-1 is specifically activated in intestinal cells beginning at the 2-fold embryonic stage embryo (Fig. 7, A-D) . Promoter function was identified through all later developmental stages with a highly restricted GFP expression in the 20 cells of the adult intestine (Fig. 7, E-H) . In these studies, the 20 cells aligned to form the entire intestine were clearly visually identified by transmitted light microscopy compared with the fluorescent images (Fig. 7, E and F) . There was a surprising restriction of CE2FT-1 expression in the intestinal cells, and all cells had equivalent expression levels based on visual observations. Virtually no GFP fluorescence was observable in nonintestinal cells in adult worms. In control experiments, we used 5Ј upstream promoter regions of other potential ␣1,2FT genes identified in our Blast search of the C. elegans genome. GFP promoter analyses with these other constructs gave no restricted GFP expression in the 20 cells of the intestine, although expression was observed in other cells (data not shown).
DISCUSSION
Glycoconjugates with the sequence Fuc␣1-2Gal-R, as in the ABO(H) blood group antigens, are expressed in a wide variety of tissues and commonly occur in the digestive mucosae of a large number of species ranging from amphibians to mammals (1, 28) . The synthesis of the ␣1,2-fucosylated structures in humans is catalyzed by two ␣1,2FTs, encoded by FUT1 and FUT2 (also known as the Se gene), which differ slightly in acceptor specificity (29 -33) . In addition, humans possess another allele termed SEC1, which is a pseudogene (33) . The orthologues for the human FUT1, FUT2, and SEC1 genes have been described in rodents and termed FTA, FTB, and FTC, respectively (34) . Little is known about the functions of the ␣1,2-fucosyltransferases and their cognate structure Fuc␣1-2Gal-R in animals.
In all species so far examined, FUT2 (Se) is expressed in the intestine. The ileal epithelium of adult mice in normal growth cages is characterized by expression of glycoconjugates with the sequence Fuc␣1-2Gal-R; however, the intestines of germfree mice are deficient in such fucose-containing structures (35) . Inoculation of the germ-free mice with Bacteroides thetaiotaomicron significantly stimulated expression of Fuc␣1-2Gal-R structures and transcripts encoding an ␣1,2FT (35) , which could be derived from either SEC1 or FUT2 (36) . It was recently shown in germ-free mice that administration of intestinal microbes stimulated expression of MFUT-II, the ortholog of human FUCT2 (Se) and rat FTB (37, 38) . The bacteria-dependent commensal stimulation of host fucosylation is a complex phenomenon involved in generating metabolic fucose to sustain bacterial flora (39) . We do not yet know whether expression of CE2FT-1 in the intestinal cells of C. elegans is induced by bacterial factors, but since the worms are constitutively grown using E. coli as a nutrient source, there may be a role for bacterial products in regulating gene expression.
Other functions of Fuc␣1-2Gal-R have also been proposed. H-type 1 oligosaccharides with the structure Fuc␣1-2Gal␤1-3GlcNAc-R are differentially expressed during mouse embryogenesis and have been proposed to be involved in early implantation events (40, 41) . The ␣1,2FT activity varies during the estrous cycle and is elevated ϳ5-fold during estrous (42) . However, implantation appears to be normal in mice genetically deficient in both murine homologs of FUT1 and FUT2 (43) .
Several other genes are known to be specifically expressed in the intestinal cells of C. elegans, such as the N-acetylglucosaminyltransferase I gene Gly14 (24) and the genes encoding cathepsin L (44) and cysteine protease (45) . There is some information about the regulatory factors driving gut-specific expression of the cysteine protease gene cpr-1. The cpr-1 gene has two upstream GATA-like motifs at Ϫ51 (GATAA) and Ϫ147 (GATAA) to the transcriptional start site (46, 47) . The results showed that the both elements are required for protein expression (46) . Similarly, it was reported that the gut-specific expression of the Hemonchus contortus gene AC-2 in C. elegans is dependent on a reverse GATA element (TTATC) at position Ϫ48 to the translation start site (47) . We have inspected the upstream 5Ј sequence of CE2FT-1 for the presence of these GATA-like motifs. There are two such GATA-like motifs at Ϫ112 (GATAA) and at Ϫ125 (GATAA) 5Ј upstream to the translational start site for CE2FT-1. Whether one or both of these elements is important for expression of the CE2FT-1 gene is not known at present.
We also inspected the 5Ј-untranslated sequences of some other C. elegans glycosyltransferase genes for the presence of GATA-like elements that might contribute to intestinal expression. The gene encoding CEFT-1, an ␣1,3FT that synthesizes Fuc␣1-3GlcNAc-R linkages (7), lacks GATA elements within Ϫ500 of the translation initiation site. Our recent expression studies on CEFT-1 expression show that it is not expressed in intestinal cells of adult C. elegans but is expressed in specific neural cells. 2 However, an open reading frame within cosmid EGAP9.3, which is in the same locus as CE2FT-1, also encodes a putative ␣1,2FT and contains one GATA-like element at Ϫ85 upstream of the translation initiation site, suggesting that it may also be specifically expressed in intestinal cells. Interestingly, the Gly14 gene encoding an N-acetylglucosaminyltransferase I (24) was shown to be expressed specifically in intestinal cells. Our inspection of the 5Ј-untranslated region of the Gly14 gene reveals that it contains two GATA-like motifs within Ϫ300 of the translation initiation site. These comparative results suggest that the GATA-like elements in the 5Ј-untranslated sequences of some glycosyltransferase genes, such as CE2FT-1, might be important in regulating their intestinespecific expression.
The amino acid sequence of CE2FT-1 displays a very low identity (5-10%) to the sequences of previously described vertebrate ␣1,2FTs. Previous studies have identified three motifs in the C-terminal regions of the vertebrate ␣1,2FT gene family termed I, II, and III (3) and in prokaryotic (Helicobacter pylori) ␣1,2FT (48), as indicated in Fig. 3 . Motifs I and III are conserved in CE2FT-1; however, motif II is not well conserved. The C-terminal or luminal domain of the protein is predicted to be Golgi-resident and constitute the catalytic domain based on analogy to mammalian ␣1,2FTs (49) . The roles of these ␣1,2FT motifs are not known, but their presence in the catalytic domain suggests that they may be involved in interactions with either acceptor glycans or GDP-Fuc. Although purely speculative, the weak conservation of motif II in CE2FT-1 might be associated with its inability to transfer to lactose and other simple Gal␤1-4Glc(NAc)-R acceptors as do the mammalian ␣1,2FTs.
Little is currently known about the roles of glycoconjugates in C. elegans development. Two of the eight sqv genes regulating vulval epithelial invagination have homologies to glycosyltransferase genes, including sqv-3, homologous to members of the ␤1,4-galactosyltransferase gene family, which may be involved in elongation of the glycosaminoglycan core linkage to Xyl-Ser, and sqv-8, homologous to two vertebrate ␤1,3-glucuronyltransferases (25, 26, 50 -52) . A third gene, sqv-7, was recently shown to encode a sugar nucleotide transporter (53) . All of these genes have been shown to be functionally involved in glycosaminoglycan biosynthesis in vivo (54) .
The C. elegans genome contains at least 22 homologues of ␣1,2FT genes, at least four genes encoding ␣1,3/4FT, one ␣1,6FT gene, and probably many more fucosyltransferase genes yet to be defined (3, 7, 55) (also see the Web site of the Consortium for Functional Glycomics at functionalglycomics. mit.edu/cgi-bin/functional_glycomics/glyt/glyt_index.cgi). For example, a cytosolic ␣1,2FT named Skp1 was recently identified in Dictyostelium (56) , which lacks significant homology to any previously identified fucosyltransferases. Skp1 is also significantly different enzymatically and structurally from CE2FT-1 and other known mammalian ␣1,2FT, in that Skp1 requires divalent cations and reducing conditions for activity, is cytosolic rather than compartmentalized, lacks a membrane anchor domain, and lacks several sequence motifs that are highly conserved in prokaryotic, microbial, and mammalian ␣1,2FTs (3).
The CE2FT-1 we have identified may be partly responsible for synthesizing the unusual Fuc␣1-2Gal␤1-6Gal-R linkages recently reported in complex-type O-glycans in adult C. elegans glycoproteins (8) . The ␣1,2-linked fucose occurred in complex structures, such as Fuc␣1-2(Gal␤1-6)Gal␤1-6(Gal␤1-3)(Fuc␣1-2)Gal␤1-3(Glc␤1-6)GalNAc␤1-4GlcNAc␤1-Ser/ Thr, in which the Fuc residue was 2-O-methylated. CE2FT-1 acts particularly well on ␤1-6-branched Gal residues, as in Gal␤1-6GlcNAc (Table I) , but not Gal␤1-4GlcNAc residues (Table I) . Interestingly, no Gal␤1-4GlcNAc residues were observed in O-glycans from C. elegans (8) . In addition, it is possible that the predicted glycan Gal␤1-4Xyl␤1-Ser generated by enzyme ␤1,4-galactosyltransferase encoded by the sqv3 gene (54) could be an endogenous acceptor for CE2FT-1, since we found that CE2FT-1 shows the highest acceptor activity toward Gal␤1-4Xyl␤-O-benzyl. However, in one study, no ␣1,2-fucosylated glycosaminoglycan core structures were found in studies on complex-type O-glycans of C. elegans (8) , but it is possible that such modifications may be restricted to core structures in only the 20 gut cells of the organism. Further studies will be required to define the exact role of CE2FT-1 and each of the other members of this large family of ␣1,2FTs in specific glycoconjugate synthesis and worm development.
